<DOC>
	<DOC>NCT01839097</DOC>
	<brief_summary>The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.</brief_summary>
	<brief_title>Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)</brief_title>
	<detailed_description>This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose (MTD) of belinostat when administered in combination with CHOP.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age 18 years or above Life Expectancy &gt; 3 months Histologically confirmed diagnosis of PTCL Patients with transformed CTCL eligible for CHOP regimen Measurable disease based on Cheson 2007 criteria Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2 Known active Hepatitis B/ Hepatitis C/ HIV infection Known, uncontrolled CNS metastases or primary CNS lymphoma Deep vein thrombosis diagnosed within 3 months Ongoing treatment for preexisting cardiovascular disease Neuropathy Grade 3 or more Previous extensive radiotherapy except limited field RT for locally advanced nasal NK PTCL or for pain palliation Prior therapy with severely myelotoxic regimens, including autologous and allogenic stem cell transplantation Prior therapy with HDAC inhibitors (except for CTCL) Inadequate hematological, hepatic, or renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PTCL</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Belinostat</keyword>
</DOC>